TBC1D2-IN-1 是一种高效、口服活性且选择性的 TBC1D2 抑制剂,其 Kd 值为 1.1 μM,可选择性抑制 TBC1D2 介导的 RAB7A-GTP 的 GTP 水解作用,促进 RAB7A 在溶酶体膜上的积累,并诱导凋亡 (apoptosis) 和自噬 (autophagy) 过程,在癌细胞中具有选择性抗增殖活性,可用于宫颈癌的相关研究。
TBC1D2-IN-1
产品编号: MS-W73445 分子式: C34H35F3N2O3 分子量: 576.65
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

TBC1D2-IN-1 是一种高效、口服活性且选择性的 TBC1D2 抑制剂,其 Kd 值为 1.1 μM,可选择性抑制 TBC1D2 介导的 RAB7A-GTP 的 GTP 水解作用,促进 RAB7A 在溶酶体膜上的积累,并诱导凋亡 (apoptosis) 和自噬 (autophagy) 过程,在癌细胞中具有选择性抗增殖活性,可用于宫颈癌的相关研究。

生物实验数据

生物活性 TBC1D2-IN-1 is a potent, orally active, and selective TBC1D2 inhibitor with a Kd value of 1.1 μM that selectively inhibits TBC1D2-mediated GTP hydrolysis of RAB7A-GTP, promotes the accumulation of RAB7A on the lysosomal membrane, and induces apoptosis and autophagy, exhibiting selective antiproliferative activity in cancer cells and being useful for research related to cervical cancer.
IC50 & Target

Caspase-3

 

Bax

 

Bcl-2

 

体外研究
(In Vitro)

TBC1D2-IN-1 (compound A1) (0.1-20 μM) 可选择性结合 TBC1D2 的 PH 结构域,与 Top 1 的结合作用较弱,且不与 Hsp90 结合。
TBC1D2-IN-1 (2 days) 可强效且选择性地抑制 HeLa 细胞增殖,其 IC50 为 0.43 μM;同时对 A549、HepG2 和 BEAS-2B 细胞的增殖具有抑制作用,对应的 IC50 值分别为 0.56、0.79 和 1.5 μM。
TBC1D2-IN-1 (0.5-1.5 μM; 24 h) 可诱导 HeLa 细胞溶酶体膜上 RAB7A 呈剂量依赖性累积。
TBC1D2-IN-1 (0.5-2 μM; 48 h) 可在 HeLa 细胞中诱导 RAB7A 蛋白水平呈浓度依赖性上调。
TBC1D2-IN-1 (0.5-2 μM; 48 h) 可在处理 48 小时后诱导 HeLa 细胞中 TBC1D2 和 VEGFR2 蛋白水平呈浓度依赖性降低,而对 Top 1 或 Hsp90 水平无显著影响。
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) 可在 HeLa 细胞中诱导强效自噬。
TBC1D2-IN-1 (0.1-10 μM; 1 h) 可在 HeLa 细胞中诱导 TBC1D2 蛋白水平发生双相变化。
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) 可在 HeLa 细胞中诱导三相凋亡反应。
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) 可诱导 HeLa 细胞的 G2/M 期比例发生非单调变化。

Immunofluorescence

Cell Line: HeLa cells
Concentration: 0.5; 1.5 μM
Incubation Time: 24 h
Result: Induced dose-dependent accumulation of RAB7A on the lysosomal membrane, visible as distinct punctate staining in treated cells compared to the diffuse cytoplasmic staining in control cells.

Western Blot Analysis

Cell Line: HeLa cells
Concentration: 0.5; 1; 1.5; 2 μM
Incubation Time: 48 h
Result: Induced a concentration-dependent increase in RAB7A protein levels.
Caused a statistically significant 2.2-fold increase in RAB7A protein levels at 2 μM compared to control.\n
Induced a concentration-dependent decrease in TBC1D2 and VEGFR2 protein levels.
Caused no significant changes in Top 1 or Hsp90 protein levels.\n
Induced dynamic changes in apoptotic regulators: p53 levels showed a modest initial increase followed by a decrease, caspase-3 and Bcl-2 levels progressively declined, and Bax levels initially decreased then markedly increased at 2 μM.

Cell Autophagy Assay

Cell Line: HeLa cells
Concentration: 0.5; 1; 1.5; 2; 2.5 μM
Incubation Time: 24 h
Result: Induced a biphasic response in lysosomal fluorescence intensity: fluorescence increased in a concentration-dependent manner up to 1.5 μM, with a 40-fold increase relative to control, then decreased at 2.5 μM due to lysosomal impairment from apoptosis.

Immunofluorescence

Cell Line: HeLa cells
Concentration: 0.1; 0.5; 1; 3; 10 μM
Incubation Time: 1 h
Result: Induced a biphasic change in TBC1D2 fluorescence intensity within 1 h: levels decreased at 0.1 μM, rebounded to a 1.6-fold increase at 1 μM, then decreased again at 10 μM compared to control.

Apoptosis Analysis

Cell Line: HeLa cells
Concentration: 0.5; 1; 1.5; 2; 2.5 μM
Incubation Time: 24 h
Result: Induced a triphasic apoptotic response: the percentage of apoptotic cells increased from 4% (control) to 26% at 1.5 μM, decreased to 16% at 2 μM, then sharply rose to 94% at 2.5 μM.

Cell Cycle Analysis

Cell Line: HeLa cells
Concentration: 0.5; 1; 1.5; 2; 2.5 μM
Incubation Time: 24 h
Result: Induced a non-monotonic change in the G2/M phase fraction: the proportion increased from 11% (control) to 34% at 0.5 μM, decreased to 4% at 1 μM, then gradually rose to 54% at 2.5 μM.
体内研究
(In Vivo)

TBC1D2-IN-1 (compound A1) (40 mg/kg;口服;隔日一次;共 28 天) 在 HeLa 细胞异种移植 BALB/c 小鼠模型中抑制肿瘤生长。

Animal Model: Female BALB/c nude subcutaneously injected with HeLa cells
Dosage: 40 mg/kg
Administration: p.o.; every other day; 28 days
Result: Achieved a 49% tumor growth inhibition rate.
Induced extensive areas of tumor necrosis via H&E staining.
Exhibited no significant body weight loss relative to controls.
Caused only mild, gefitinib-comparable histopathological alterations in major organs, including mild capillary wall thickening in lungs and occasional tubular swelling and edema in kidneys.

化学信息

分子量 576.65
分子式 C34H35F3N2O3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础